Stocktoria
Neurogene Inc. NGNE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-07
Neurogene Inc. statistics & valuation
Market cap$506.1M
P / B1.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -8930.3% | — | — | — |
| Net margin | — | -8123.7% | — | — | — |
| FCF margin | — | -7720.1% | — | — | — |
| Return on assets | -31.3% | -22.4% | -16.3% | -50.5% | -37.2% |
| Return on equity | -34.1% | -24.2% | -19.5% | 37.9% | 66.1% |
| Current ratio | 16.56 | 20.84 | 8.72 | 12.74 | 16.67 |
| Revenue growth | -100.0% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001404644 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.